Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.
Lixia LiXiaohui HuangJingxian LiuChao LiZhiyan LinRongrong RenYan ZhangHaoshu DingJihui ChenYanfei MaoPublished in: Infection and drug resistance (2024)
≥ 2.3 µg /mL and AUC ≥ 82.0 mg h/L may increase PMB-associated AKI incidence. PMB dose should be adjusted based on TDM to ensure efficacy.